Dulac Edward J III 4
4 · Intellia Therapeutics, Inc. · Filed Jan 7, 2026
Insider Transaction Report
Form 4
Dulac Edward J III
EVP, Chief Financial Officer
Transactions
- Sale
Common Stock
2026-01-05$9.21/sh−6,379$58,751→ 99,683 total
Footnotes (1)
- [F1]Represents a mandatory "sell-to-cover" transaction for the purpose of satisfying the reporting person's tax withholding obligation upon the vesting of RSUs on January 1, 2026, and does not represent a volitional trade by the Reporting Person.